Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Zurich
Headquarters: Zurich, Switzerland
Website: http://www.uzh.ch/index_en.ht...
Year Founded: 1833
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 19, 2024
Management Tracks
Bumpus leaving FDA
Plus: Ra Capital names three new partners and updates from Anaveon, Adicet, Bio Usawa and Neopredics
BioCentury | Nov 6, 2024
Distillery Therapeutics
Inhibiting JAK-induced STAT1 signaling for toxic epidermal necrolysis
BioCentury | Feb 20, 2024
Emerging Company Profile
EraCal: fishing for new obesity targets
Swiss company’s zebrafish platform identifies new appetite suppressant targets without unwanted adverse effects
BioCentury | Jan 20, 2024
Discovery & Translation
Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 14, 2023
Discovery & Translation
Ubiquitin-regulation for tauopathies; plus Regeneron’s IL2RG mAb for T cell-driven disease and more
BioCentury’s round-up of translational news
BioCentury | Dec 1, 2022
Management Tracks
Gasal to be CMO at Anaveon
Plus Anderson joins Centessa and updates from Mnemo and NXI
BioCentury | Aug 11, 2022
Emerging Company Profile
Vector: targeted gene delivery with immune-shielded, high-capacity virus-like particles
Versant start-up using $30M series A to advance its gene delivery platform based on tech from Andreas Plückthun’s University of Zurich lab
BioCentury | Jun 7, 2022
Finance
Zurich-based ImmunOs taps U.S.-EU syndicate for $74M series B, expands footprint
Swiss immuno-oncology start-up building presence in Maryland as lead HLA-derived program nears clinic
BioCentury | Jun 1, 2022
Management Tracks
Zentalis co-founder Gallagher now president
Plus DTx hires Huang as CMO and updates from neoX, Altoid and more
BioCentury | May 5, 2022
Discovery & Translation
Intima’s public neoantigen discovery platform; plus MS autoantigens and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 95